My Top 4 Stocks to Buy in Early 2026

Alphabet and Nvidia are highlighted as primary ways to gain exposure to the AI cycle, with Google Cloud revenue up 34% year-over-year to $15.2 billion and a $155 billion backlog, and Nvidia projecting >$500 billion revenue potential for Blackwell/Rubin systems through 2026 while securing significant TSMC packaging capacity and licensing Groq technology. AbbVie shows resilient core growth—Skyrizi revenue rose 46% to $4.7 billion and Rinvoq rose 34% to $2.2 billion, with combined sales expected near $31 billion by 2027 and late-2026 Phase 3 readouts for an ABBV gene therapy—supported by a 3.2% dividend and buybacks. Interactive Brokers benefits from higher rates and client flows (NII +21% to $967 million; client cash $150 billion; 4 million customers; client equity >$750 billion), plus product and charter initiatives that could expand services and institutional demand.

Analysis

Market structure: NVDA and Alphabet (GOOGL/GOOG) are primary beneficiaries as AI demand shifts from commodity CPUs to accelerated systems and cloud services; NVDA capturing system-level margins and booking >50% of TSM advanced packaging capacity signals structural pricing power in GPUs and AI servers, while Alphabet’s $155B cloud backlog and 34% cloud growth underpin recurring cash flow. Financial-platform winners like IBKR earn outsized NII in a higher-for-longer rate regime—client cash at $150B and 21% YoY NII growth show deposit-heavy platforms widening profit pools. Biotech pick ABBV benefits from durable cash flows and near-term phase-3 and approval catalysts that compress risk relative to small-cap biotech peers.

Risks: Tail scenarios include U.S./export controls or accelerated antitrust action vs NVDA that could remove key markets (high-impact, <10% probability), a failed ABBV phase-3 late 2026 (-20%+ stock shock), or IBKR national-trust charter denial limiting TAM expansion. Immediate (days) risk: earnings-guidance beats/misses; short-term (weeks–months): packaging conversion and backlog realization; long-term (quarters–years): competitive ASICs, pricing pressure, and regulatory rulings. Hidden dependencies include TSM packaging cadence, Groq licensing indicating emergent LPU competition, and macro-driven ad spend sensitivity for Alphabet.

Trades and timing: Favor structured exposure to NVDA (convex long via spreads) and direct GOOGL equity for durable cash flows; buy ABBV for income plus asymmetric pipeline upside ahead of 2026 readouts; size IBKR as a rates proxy and deposit-play. Use 12–18 month option horizons to capture system-cycle upside while limiting downside; add on pullbacks >10% and trim on consecutive quarters of margin contraction. Monitor specific triggers: NVDA quarterly guide, TSM packaging utilization, ABBV phase-3 readout (late 2026), and IBKR charter decision (6–12 months).

Contrarian lens: Consensus understates operational bottlenecks—if TSM packaging fails to scale, NVDA upside is timing-constrained and implied multiples may compress; market may be overpaying for ABBV’s pipeline optionality (a negative phase-3 could cut >20%); IBKR’s crypto/stablecoin angle is a shallow moat if rates normalize and securities lending commoditizes. Historically, tech supply chokepoints (2000s fab constraints) led to order delays and volatile re-rates—expect erratic price action around capacity and regulatory news, not steady linear appreciation.

Key Decisions for Investors

• Establish a 1.5–2.0% portfolio risk position in NVDA via Jan 2027 call spreads (buy ~30% OTM / sell ~60% OTM) to capture system-cycle upside while capping premium; increase to 3% risk if NVDA reports backlog conversion >30% of guidance in next quarterly report.
• Buy 2–3% position in GOOGL shares for core AI/cloud exposure; add to 4% on a price decline >12% or if Google Cloud posts >35% YoY revenue growth next quarter; hedge initial 1% exposure with short-dated puts (30–60 days) equal to 1% notional to protect vs ad-revenue shock.
• Allocate 3–4% to ABBV as an income-plus-catalyst trade (3.2% yield); sell covered calls to boost yield by ~2% if comfortable capping upside; reduce to 50% size or cut on an adverse Phase 3 readout (expect >20% downside on negative outcome) targeted late 2026.
• Initiate a 2% long position in IBKR common stock as a rates/deposit play; increase to 4% if NII growth >15% QoQ or client cash >$160B. Implement a relative pair: long IBKR vs short an unprofitable retail-fintech basket (~1:1 notional) for 6–12 months to harvest deposit/NII arbitrage, and exit/reassess upon national trust bank charter decision (6–12 months).